Liptis Pharmaceuticals USA, Inc. v. Ingraham Group, LLC

CourtDistrict Court, D. Puerto Rico
DecidedJune 7, 2023
Docket3:21-cv-01485
StatusUnknown

This text of Liptis Pharmaceuticals USA, Inc. v. Ingraham Group, LLC (Liptis Pharmaceuticals USA, Inc. v. Ingraham Group, LLC) is published on Counsel Stack Legal Research, covering District Court, D. Puerto Rico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Liptis Pharmaceuticals USA, Inc. v. Ingraham Group, LLC, (prd 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF PUERTO RICO

Liptis P harmaceuticals USA,

Inc., Civil. No. 21-cv-01485(GMM) Plaintiff, v. Ingraham Group, LLC; Sami Omar, Defendants.

OPINION AND ORDER Pending before the Court is Ingraham Group, LLC (“Ingraham”) and Mr. Sami Omar’s (“Mr. Omar”) (collectively “Defendants”) Motion to Stay Proceedings under the Colorado River Doctrine. (Docket No. 57). The Motion to Stay is GRANTED. I. RELEVANT FACTUAL AND PROCEDURAL BACKGROUND On October 5, 2021, Liptis Pharmaceuticals USA, Inc. (“Liptis USA” or “Plaintiff”) filed a Complaint against Ingraham. (Docket No. 1). On December 29, 2021, it filed an Amended Complaint to join Mr. Omar as a defendant. (Docket No. 13). Therein, Liptis USA alleged that Defendants, Mr. Omar and Ingraham, —knowingly and maliciously— interfered with a January 2018, ten-year contract, (“2018 Agreement”) between Liptis USA and Liptis for Pharmaceuticals and Medical Devices SAE, formerly known as Liptis Egypt for Pharmaceuticals and Medical Devices SAE (“Liptis Egypt”). Plaintiff’s claim is brought pursuant to Article 1802 of the Puerto Rico Civil Code (Puerto Rico Federal Case). Id. at 6. Plaintiff argues that Ingraham, a limited liability company registered with the Puerto Rico Department of State, was solely

created to maliciously interfere with the 2018 Agreement. Plaintiff reasons that to the extent that Liptis Egypt was its only client, had no previous history of operations with them, and none since the Liptis Egypt transactions, there was an ulterior illegal motive in Ingraham’s creation. Id. at 3. Plaintiff alleges that around November 2020, Mr. Omar, using Ingraham as a corporate alter ego, knowingly and maliciously interfered with the 2018 Agreement and benefited from receiving multiple payments through wire transfers. Id. at 4. Consequently, Plaintiff claims damages resulting from the alleged interference. On June 30, 2022, Ingraham filed its Answer to the Amended

Complaint. (Docket No. 41). On December 19, 2022, Mr. Omar filed his Answer to the Amended Complaint. (Docket No. 55). On February 13, 2023, Defendants filed a Motion to Stay Proceedings under the Colorado River Doctrine. (Docket No. 57). They claim that the next day after filing the Amended Complaint before this Court, on December 30, 2021, Liptis USA filed a First Amended Verified Complaint against Liptis Egypt —the other party to the 2018 Agreement with which Defendants allegedly interfered— before the Supreme Court of the State of New York, County of Rockland, in the case captioned Liptis Pharmaceuticals USA Inc v. Liptis for Pharmaceuticals and Medical Products SAE, and docketed under Index No. 35274/2021 (“New York State Case”). Id. at 2. Defendants assert that in the New York State Case, Liptis USA

alleges trademark infringement and unfair competition under common law; trade name and trademark dilution under New York General Business Law; breach of contract; breach of the covenant of good faith and fair dealing, and unjust enrichment. Id. They add that, under the 2018 Agreement, Liptis USA would supply raw material to Liptis Egypt who could then manufacture and sell certain pharmaceutical, nutraceutical, and consumer healthcare products in Egypt and use, in a limited fashion, certain Liptis USA’s intellectual property rights. Id. at 2-3. In the New York State Case, Liptis USA also claimed that Liptis Egypt breached the 2018 Agreement, and others1, by cutting

off all business with them and engaging in an illegal competition. They contend that this constitutes a breach of the exclusive supply, manufacture, and licensing contract. As per Liptis USA’s allegations in the New York State Case, in 2020, Liptis Egypt purportedly issued $4.66 million to Ingraham as payment for supply

1 Liptis USA alleges the 2018 Agreement is related to the 2008 and 2016 agreements also in question before the New York State Case. They maintain the 2018 Agreement modifies said contracts. See NYSCEF Docket No 113 at 22. of raw materials for products subject to the 2018 Agreement at the same prices as Liptis USA would have under the 2018 Agreement. Id. On January 19, 2022, Liptis Egypt filed its Verified Answer to First Amended Complaint with Counterclaim in the New York State

Case. It argued that the 2018 Agreement entered between the parties was null and void ab initio because the person acting on behalf of Liptis USA lacked authority to enter such contracts. Id. at 4; Exhibit 2 at 21. Additionally, Liptis Egypt posited that, even if the 2018 Agreement was valid, there was no breach of contract. Id. The New York State Case is pending. Hence, Defendants argue that the New York State Case and the Puerto Rico Federal Case are grounded on the existence of the 2018 Agreement. They add that while the validity of the 2018 Agreement has been challenged in the New York State Case, here Plaintiff imputes Ingraham with tortious interference with that same

contract. They argue a stay is warranted under the Colorado River Water Conservation Dist. v. United States, 424 U.S. 800 (1976), until after the New York State Court decides on the validity and enforceability of the 2018 Agreement. On March 13, 2023, Liptis USA filed its Motion in Opposition to Stay in Proceeding under the Colorado River Doctrine. (Docket No. 66). Liptis USA argues that the New York and Puerto Rico claims are not parallel, since the New York State Case is: (1) “based around the validity of a contractual obligation Liptis USA went into with Liptis Egypt, a complete stranger to the case at hand”. Id. at 4; (2) Defendants are not parties to the New York action; and (3) Puerto Rico’s federal court is the commonsense forum for any claim against Ingraham and Mr. Omar, as is it involves a Puerto

Rican corporation ruled by local law and jurisprudence. Id. Liptis USA further argues that after weighing all the eight factors established in Colorado River, supra, none of them lean in favor of a stay. According to Liptis USA, the first and second factors are neutral, since neither the Puerto Rico Federal Case nor the New York State Case involve the comprehensive disposition of rights in a particular property (res), and New York is just as geographically inconvenient for the Defendants as Puerto Rico is for the Plaintiff. As to the third factor, Liptis USA argue that there is no exceptional basis that places this case “beyond the pale of duplicative proceedings”, as this case “involves a simple

contract dispute requiring application of settled local law”. Id. at 5. Regarding the fourth factor, Liptis USA alleges that it remains neutral, since the progress of the New York State Case bears no weight in the Puerto Rico Federal Case. They contend that although the New York State Case was filed before the Puerto Rico Federal Case, they are not parallel because they bare no identical claims or parties. Plaintiff also argues that the fifth factor is neutral because the Puerto Rico Federal Case does not raise an issue of federal law which is better resolved by a federal court, nor does it involve particularly novel questions of state law. As to the sixth, seventh and eighth factors, likewise, Liptis USA argues they are neutral, and unapplicable to the case at hand, as it is not a parallel litigation. Id. at 6.

On March 30, 2023, Defendants filed their Reply in Support of Motion to Proceedings under the Colorado River Doctrine. (Docket No. 74). In essence, they argue that further litigation in the Puerto Rico Federal Case is a waste of judicial and the parties’ resources, since the main threshold issue is the existence, validity and/or alleged breach of the 2018 Agreement on which this case is predicated on. Id. at 4.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McClellan v. Carland
217 U.S. 268 (Supreme Court, 1910)
Rivera-Feliciano v. Acevedo-Vila
438 F.3d 50 (First Circuit, 2006)
United States v. Fairway Capital Corp.
483 F.3d 34 (First Circuit, 2007)
Villa Marina Yacht Sales, Inc. v. Hatteras Yachts
947 F.2d 529 (First Circuit, 1991)
Nazario-Lugo v. Caribevision Holdings, Inc.
670 F.3d 109 (First Circuit, 2012)
Valjeanne Currie v. Group Insurance Commission
290 F.3d 1 (First Circuit, 2002)
Estee Lauder Companies Inc. v. Batra
430 F. Supp. 2d 158 (S.D. New York, 2006)
Malave v. Centro Cardiovascular De Puerto Rico Y Del Caribe
485 F. Supp. 2d 6 (D. Puerto Rico, 2007)
VALLE-ARCE v. Puerto Rico Ports Authority
585 F. Supp. 2d 246 (D. Puerto Rico, 2008)
Directv, Inc. v. Imburgia
577 U.S. 47 (Supreme Court, 2015)
Jiménez v. Rodríguez-Pagán
597 F.3d 18 (First Circuit, 2010)
Dolphin International of Puerto Rico, Inc. v. Ryder Truck Lines, Inc.
127 P.R. Dec. 869 (Supreme Court of Puerto Rico, 1991)
Jusino Figueroa v. Walgreens of San Patricio Inc.
155 P.R. Dec. 560 (Supreme Court of Puerto Rico, 2001)
Glassie v. Doucette
55 F.4th 58 (First Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
Liptis Pharmaceuticals USA, Inc. v. Ingraham Group, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/liptis-pharmaceuticals-usa-inc-v-ingraham-group-llc-prd-2023.